1. Introduction {#s0005}
===============

Coherent brain network activity is an indicator of healthy brain functioning and depends on a balanced interplay between inhibitory and excitatory neuronal activity ([@bb0105]; [@bb0120]; [@bb0345]; [@bb0410]). Neurodegenerative diseases are characterized by an aggregation of various pathological proteins ([@bb0320]) that is associated with compromised coordination of neuronal brain activity ([@bb0040]; [@bb0200]). Alzheimer\'s disease (AD) is the most frequent cause for neurodegenerative dementia at high age and is characterized by a decade long preclinical phase during which beta-amyloid pathology manifests, while cognitive performance remains normal for a long time ([@bb0095]; [@bb0370]). Moreover, the presence of beta-amyloid in AD risk-populations is associated with distinct changes in brain network activity, as indicated by altered patterns of synchronous neural activity of functionally connected brain regions ([@bb0125]; [@bb0255]; [@bb0350]; [@bb0360]; [@bb0375]; [@bb0390]). Interestingly, beta-amyloid related connectivity changes particularly affect intrinsic cognitive networks such as the default mode network (DMN) ([@bb0050]; [@bb0180]; [@bb0355]). A characteristic feature of intrinsic networks such as the DMN is that they are constituted by distinct sets of functionally connected *'hubs'* that synchronously activate at rest ([@bb0045]; [@bb0165]; [@bb0305]). Activity of intrinsic brain networks may be inferred on by measuring 'static' connectivity of neuronal tissue to a major network hub using blood oxygen level dependent (BOLD) functional magnetic resonance imaging (fMRI) at rest ([@bb0130]). More recently, also approaches for measuring 'dynamic' connectivity have been established that allow for the variability of functional connectivity within networks over time ([@bb0065]; [@bb0175]; [@bb0190]; [@bb0285]).

The posterior cingulate and precuneus (PCP) region is a major 'hub' in various intrinsic brain networks, and pathological change pertaining to the PCP is a robust finding in preclinical AD ([@bb0100]; [@bb0245]; [@bb0355]; [@bb0385]). Moreover, as the PCP plays a central role for episodic memory processing, this is consistent with episodic memory typically being first affected when cognitive impairment manifests in the course of AD ([@bb0010]; [@bb0075]).

GABA and glutamate represent major excitatory and inhibitory neurotransmitters in the human central nervous system. A concatenation of preclinical studies suggest that beta-amyloid aggregation is linked to local dysfunction of neuronal inhibition and excitation ([@bb0030]; [@bb0055]; [@bb0280]; [@bb0405]). However, to our knowledge, the interaction between GABA, glutamate and beta-amyloid has not been investigated in human in vivo study populations yet.

Allowing for these earlier findings that suggest an intimate relationship between beta-amyloid and both regulation of neuronal inhibition and excitation, we hypothesized that the impact of pathological beta-amyloid on intrinsic brain network activity is moderated by GABA and glutamate. Thus, aims of the current study were: (1) to determine presence and activity of intrinsic beta-amyloid associated brain networks in cognitively unimpaired old-aged adults at rest; (2) to establish whether Glutamate and GABA moderate effects of beta-amyloid on network activity.

To this effect, GABA and glutamate were specifically assessed in gray and also white matter of the PCP using magnetic resonance spectroscopic imaging (MRSI) based on the 'free induction decay acquisition localized by outer volume suppression' (FIDLOVS) methodology ([@bb0185]) at ultra-high field strength of 7 Tesla (7 T) for increased spatial resolution of spectral information and increased signal-to-noise ratio (SNR). Beta-amyloid plaque density was assessed by 11C-Pittsburgh-Compound B (PiB) positron emission tomography (PET) ([@bb2555]). '*Static*' functional connectivity was measured using the PCP as a seed for BOLD synchronicity at rest ([@bb0425]). In addition, whole-brain *'dynamic'* connectivity was assessed as a measure of the temporal dynamics of BOLD synchronicity patterns ([@bb0015]) by applying a sliding time window approach ([@bb0235]; [@bb0315]).

2. Materials and methods {#s0010}
========================

2.1. Study population {#s0015}
---------------------

The study sample included a total of 29 (17 males, 12 females) cognitively unimpaired old-aged adults (mean age: 69.75 ± 5.57 years), who where recruited from an ongoing cohort study of ours ([@bb0140]; [@bb0330]; [@bb0375]). Due to missing MRSI data, not all 29 participants were included in the subsequent combined connectivity analyses (see [Table 1](#t0005){ref-type="table"}). To ensure normal cognitive performance, potential study participants were cognitively evaluated by applying a battery of neuropsychological tests as indicated earlier ([@bb0300]). These included the Mini-mental State Examination (MMSE) ([@bb0115]) as a screening test for present cognitive impairment. For detection of isolated neuropsychological deficits in potential study participants, additionally the Revised Boston Naming Test (BNT) ([@bb0265]), Digit Spans Backward ([@bb0160]), Trail Making Test (TMT) B/A ([@bb0400]); Verbal Learning And Memory Test (VLMT): delayed recall ([@bb0230]) were performed. Exclusion criteria were: any present medication that may affect cognition, general magnetic resonance imaging (MRI) exclusion criteria, contraindications against venipuncture, clinically relevant changes in red blood cell count, any acute severe medical, neurological or psychiatric condition, present or past drug abuse, allergy to the PET tracer 11C-PiB, significant earlier exposure to radiation. Moreover, any participant who showed MRI evidence of infarction, focal or significant hemorrhagic lesions, was excluded from this study. The Apolipoprotein E ε4 allele was assessed to detect possible overrepresentation of genetic risk for AD and brain amyloidosis in the investigated sample ([@bb0090]; [@bb0215]). All study procedures were carried out in accordance with regulatory requirements (Kantonale Ethikkommission Zürich, [www.kek.zh.ch](http://www.kek.zh.ch){#ir0005}) and the Declaration of Helsinki. Written informed consent was obtained from all candidates prior to participation in thi study.Table 1Demographics of the sample population. The last column contains p-values of two-sample *t*-tests to ensure there are no significant demographic differences between the GABA and Glutamate sample.Table 1AllGABAGlutamatep-valuesN total292428N/AAge70.03 ± 5.7769.54 ± 5.7669.43 ± 5.370.91Males1714170.86ApoE-e48770.74MMSE29.41 ± 0.8129.46 ± 0.8529.48 ± 0.820.88BMI25.62 ± 3.7724.95 ± 2.9925.44 ± 3.780.57Education (in years)15.83 ± 2.4816.00 ± 2.5415.79 ± 2.380.88Cortical PiB\
Ratio\
PiB +1.25 ± 0.34\
\
31.22 ± 0.29\
\
21.21 ± 0.27\
\
20.93\
\
N/A

2.2. Acquisition of MRI data {#s0020}
----------------------------

All participants underwent a single scanning session in a Philips Achieva 7-Tesla (7 T) whole-body scanner (Philips Healthcare, Best, The Netherlands) equipped with a Nova Medical quadrature transmit head coil and a 32-channel receive coil array. High-resolution T1-weighted 3D-MPRAGE structural images (repetition time (TR)/echo time (TE) = 8.22 ms/3.74 ms, voxel size = 0.86 × 0.86, scan duration = 653.71 s, slice thickness = 0.9 mm, flip angle = 7°, FOV = 220 × 157.5 × 198.36) were obtained for referencing, automated multi-channel image segmentation, and localization of the volumes of interest (VOIs) for magnetic resonance spectroscopic imaging (MRSI), as done in earlier studies of ours ([@bb0340]; [@bb0335]). In brief, we acquired a refined high-resolution direct free-induction-decay (FID) sequence (acquisition delay = 2.5 ms, TR = 644 ms, in-plane resolution = 3.5 × 3.5 mm2, slice thickness = 12 mm, scan duration = 1762s) based on \"FID acquisition, localized by outer volume suppression\" (FIDLOVS) ([@bb0185]), with water suppression similar to variable power RF pulses with optimized relaxation delays (VAPOR) ([@bb0395]), but without outer volume or fat suppression ([@bb0035]). Dynamic B0 shimming was conducted to reduce magnetic field inhomogeneities particularly due to the absence of outer volume or fat suppression ([@bb0110]). To obtain the exact anatomical reference of these images, a T1-weighted structural turbo spin echo (TSE) image (TR/TE = 5.7 ms/2.9 ms, resolution = 0.9 × 0.9 × 1.5 mm) was acquired using the same FOV dimensions as the MRSI slab. Resting-state fMRI data for each subject was acquired using an echo planar imaging (EPI) sequence (TR = 2500 ms, slice thickness = 3 mm, flip angle = 45°, voxel size = 1.719 × 1.719 mm, scan duration = 537.5 s, number of slices = 50, FOV = 220x150x220mm).

2.3. Defining the posterior cingulate/Precuneus (PCP) slab for metabolite measurement {#s0025}
-------------------------------------------------------------------------------------

To assess MRSI metabolites in the Posterior Cingulate/Precuneus (PCP), the Hammers atlas, a 3-dimensional maximum probability atlas of the human brain containing 83 anatomical labels ([@bb0155]; [@bb0170]), was modified in-house to generate a binary mask of the PCP. This ROI comprised the PCP, corresponding to the Brodmann areas BA 31 and the medial parts of BA 7. The superior and inferior anatomical borders were defined by the extent of the MRSI slab in the z direction, the rostral border by the posterior part of the Anterior Cingulate cortex, and the posterior border by the Postero-occipital fissure. Custom ROIs were acquired using a pipeline applied to the anatomical ROIs of the PCP per subject ([@bb0335]).

2.4. Acquisition of PET data {#s0030}
----------------------------

Cortical beta-amyloid deposits were measured using Positron Emission Tomography (PET) with the tracer 11-C Pittsburgh Compound B (PiB) ([@bb2555]). Participants were intravenously administered a dose of approximately 350 MBq of the tracer and amyloid deposition was estimated based on late frame signals representing 50--70 min post-injection. Measures of cerebral beta-amyloid load per subject was derived from the ratio of standardized uptake values (SUV) of cortical PiB-VOIs, referenced to cerebellar gray matter SUV after co-registration using the PMOD brain tool (PNEURO) software, Version 3.4 (PMOD Technologies Ltd., Zurich, Switzerland) as described in our previous studies ([@bb0335]; [@bb0375]). Standardized PiB-SUV were used to calculate cortical to cerebellar PiB retention ratio units ("cortical-PiB") ([@bb0195]), and to determine "amyloid-positive" status using an earlier defined threshold of ours ([@bb0140]).

2.5. Processing of magnetic resonance spectroscopic imaging (MRSI) data {#s0035}
-----------------------------------------------------------------------

The post-processing pipeline of MRSI data conducted, is identical to the pipeline used in an earlier publication ([@bb0335]). Tissue-specific anatomical sub-regions of PCP were defined on the MRSI slab that covered the PCP region. GABA and glutamate, referenced to Creatine, were estimated with LC model ([@bb0290]) from averaged MRSI spectra from PCP gray matter and white matter separately.

Sufficient MRSI quality was determined by visual inspection of all spectra ([Fig. 1](#f0005){ref-type="fig"}), as conducted in previous studies ([@bb0340]; [@bb0335]) and applying recommended cut-offs for SNR (Oz G, Alger JR, Barker PB, et al. Clinical proton MR spectroscopy in central nervous system disorders. Radiology. 2014 Mar;270(3):658-79). Further, we only considered spectra with relative Cramér-Rao Lower Bounds (CRLB) \<30%, despite the common practice of using relative CRLB \<20%. We chose this more liberal threshold, as a strict usage of relative CRLB may introduce bias by underestimating changes in metabolites with low levels ([@bb0225]), e.g. GABA.Fig. 1Image processing and analysis workflow of PET, MRSI and fMRI data.Fig. 1

2.6. Processing of fMRI data and assessment of dynamic functional connectivity {#s0040}
------------------------------------------------------------------------------

Structural and functional images were preprocessed using a standardized in-house developed pipeline ([@bb0315]). This pipeline was implemented with MATLAB scripts (MATLAB 2015b, Version 8.6, MathWorks Inc., Natick, MA, USA), including functions from SPM8 and SPM12 ([www.fil.ion.ucl.uk/spm](http://www.fil.ion.ucl.uk/spm){#ir0010}) and DPARSFA toolboxes ([@bb0070]). Preprocessing parameters used in this study are identical to those used in an earlier dynamic functional connectivity study ([@bb0300]). The images were spatially realigned and smoothed and nuisance variables were regressed out from the regional time series. The functional volumes were then regionally parcellated using the automated anatomical labelling (AAL) atlas. Regional mean time series were extracted by averaging the preprocessed BOLD signal over all voxels in each region.

A sliding time window approach was used (window size: 24TRs (=60s), step: 1TR (=2.5 s)) to calculate the time-varying correlations between BOLD fluctuations in distinct brain regions. PCA was then used to extract meaningful connectivity patterns *('eigenconnectivities'*) that best capture dynamic functional connectivity ([@bb0300]). These patterns are characterized by two main configurations: positive/red connections denote an increase in connectivity between a set of nodes, whereas negative/blue illustrate decreased connectivity between a given set of nodes.

The weighted time contributions of each eigenconnectivity (network) were calculated by projecting dynamic functional connectivity on a select number of eigenconnectivities. An eigenconnectivity number of 10 was sufficient to explain 37% of data variance when taking the diagonal of the decomposed PCA matrix, as indicated in previous studies of ours ([@bb0235]; [@bb0295]). The measure assessed according to our predictor variables was the *percentage of positive weights* of each eigenconnectivity, which illustrates the propensity of an eigenconnectivity\'s preference towards increased connectivity between the red nodes and less connectivity between the blue nodes. Network signs (positive or negative) are thus used to illustrate alternations between: (1) increased connectivity (positive/red connections); and (2) decreased connectivity (negative/blue connections) between a set of nodes. Percentage of positive weights represents the amount of time a network contributes with a positive sign. A positive sign weight indicates a preference for a network to contribute to the dynamic functional connectivity in the first configuration (increased connectivity), whilst a negative sign weight indicates a preference for an eigenconnectivity to contribute in the second configuration (decreased connectivity).

Multimodal neuroimaging approach of combined 7 T FIDLOVS MRI (gray matter GABA and glutamate), 11C PiB-PET (beta-amyloid burden) and 7 T BOLD fMRI at rest (static and dynamic functional connectivity).

2.7. Statistical tests {#s0045}
----------------------

All statistical tests were carried out using MATLAB (2015b, Version 8.6), the Statistics and Machine Learning Toolbox (Version 10.0) and the CONN toolbox ([@bb0425]). Static functional connectivity changes in the context of cortical beta-amyloid and GABA and Glutamate levels in the PCP were assessed using the CONN toolbox with the MRSI PCP slab as a seed. Thus, any connectivity changes observed would regionally overlap with regions, where GABA and glutamate measures are obtained. Altered connectivity between identified regional clusters and the PCP were compared by post-hoc tests using CONN. R^2^ values were obtained to investigate the degree of correlation between BOLD fluctuations of these clusters and the PCP.

Since the obtained PiB-load and metabolite measures are continuous variables, correlations between predictors and time contribution and percentage positive weights of the dynamic functional connectivity were explored. A Canonical Correlation Analysis (CCA) was conducted to investigate any interaction effects of beta-amyloid with GABA and glutamate on dynamic functional connectivity measures. Statistical tests were all corrected for multiple comparisons using False Discovery Rate (FDR) correction according to the Benjamini-Hochberg procedure ([@bb0025]). This was done by obtaining the Benjamini-Hochberg critical values for each *p*-value based on the formula (*i/m*)*Q*, where *i* denotes the individual p-value\'s rank, *m* is the number of tests and *Q* represents the false discovery rate (0.05). The original values were then compared to the critical B---H values and the largest *p* value that has *p* \< (*i/m*)*Q* is significant and all the *p*-values smaller than it are also considered significant. [Fig. 1](#f0005){ref-type="fig"} illustrates the image processing and workflow of all related statistical analyses.

3. Results {#s0050}
==========

3.1. Sample population {#s0055}
----------------------

Due to missing data or insufficient MRSI quality, 5 participants were excluded from the GABA analysis and 1 participant from the Glutamate analysis (see [Table 1](#t0005){ref-type="table"}). In the remaining spectra, SNR was 14.2 + 4.8 in PCP GM and 13.0 ± 4.7 in PCP WM, respectively. Relative CRLB for GABA and Glutamate was 10.4 ± 4.0% and 4.3 ± 2.6% in GM, and 16.0 ± 7.0% and 5.8 ± 3.2% in WM, respectively. Neuropsychological testing indicated normal cognitive performance, as reflected by high group scores in the MMSE (29.41 ± 0.81). The study population included 8 APOE4 carriers, and 3 amyloid-positive participants ([Fig. 2](#f0010){ref-type="fig"}).Fig. 2Measuring Regional Gray and White Matter Levels of GABA and Glutamate with Tissue-specific MRSI at 7 T.Fig. 2

A: Axial representation of the Posterior Cingulate/Precuneus (PCP) gray matter (red) and white matter (blue) regions used for the MRSI analysis. Exemplary spectra analyzed using the LC Model to estimate average metabolite-levels between the gray (B) and white (C) matter. The colored lines denote the spectral fit and the black lines denote the residuals. Arrows mark the peaks for Glutamate (dashed) and GABA (solid). D: GABA and glutamate levels (each referenced to creatine) where higher in PCP gray matter (GM) compared to white matter (WM) (GABA: *t*(45) = 2.26, *p* *=* 0*.029*; Glutamate: *t*(50) = 4.24, *p* *\<* 0*.001*). The asterisk indicates significance at *p* \< 0.05.

3.2. GABA and glutamate in PCP gray and white matter {#s0060}
----------------------------------------------------

By applying MRSI for assessing tissue-type specific metabolite measures, significantly higher levels of both GABA and Glutamate resulted for gray matter compared to white matter (GABA, gray matter: mean ± SD: 0.42 ± 0.27; GABA, white matter: 0.3 ± 0.17; *t*(45) = 2.26, *p* *=* 0*.03;* Glutamate, gray matter: mean ± SD: 1.32 ± 0.5; Glutamate, white matter: 0.84 ± 0.26; *t*(50) = 4.24, *p* *=* 0*.0001*). Subsequent analyses used only gray matter measures of GABA and glutamate, as brain activity and beta-amyloid were exclusively measured in gray matter and previous work indicated that MRSI metabolite changes in PCP gray matter are more relevant compared to PCP white matter in a context of aging, cognition, and beta-amyloid ([@bb0340]).

3.3. Beta-amyloid, GABA and glutamate alter static PCP connectivity {#s0065}
-------------------------------------------------------------------

Static PCP functional connectivity according to global beta-amyloid load and GABA and glutamate levels in PCP gray matter were assessed using the CONN toolbox. Cortical beta-amyloid load was inferred from PiB measures, thus the term beta-amyloid will be used forthwith instead of PiB for clarity.

Relationships between cortical beta-amyloid and PCP connectivity was observable for 10 clusters (6 clusters with negative connectivity). Positively connected clusters primarily included the Lingual Gyrus, the left Temporal Fusiform Cortex (posterior division), left Lateral Occipital Cortex, the left Inferior Temporal Gyrus, the left posterior Middle Temporal Gyrus, the anterior Parahippocampal Gyrus, the Hippocampus, the Putamen, Thalamus, the Amygdala, the left Temporal Pole, and the right Occipital Fusiform Gyrus. Regions with negative PCP connectivity included the Frontomedial Cortex, the Subcallosal cortex, the Frontal Orbital Cortex, the right posterior Inferior Temporal Gyrus, the right posterior Middle Temporal Gyrus, and the left posterior Parahippocampal Gyrus ([Fig. 3](#f0015){ref-type="fig"}).Fig. 3Beta-amyloid Load Relates to Changes in Static Functional Connectivity.Fig. 3

Rendered 3D brains and coronal brain slices showing regions with increased (red) connectivity and decreased (blue) PCP connectivity associated with global cortical beta-amyloid load. Cluster thresholds for visualization of these clusters were different from the analysis with a cluster threshold of *p* *\<* 0*.05* (FDR-corrected). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

The interaction of GABA and beta-amyloid affected a wider array of regions (18 clusters), with positively associated clusters covering frontomedial regions, such as Middle Frontal Gyrus, the left Superior Frontal Gyrus, the right Frontal Orbital Cortex, the right Frontal Pole, the Precuneus, the Inferior Frontal Gyrus pars triangularis and the Paracingulate Gyrus and some cerebellar regions. Clusters with negative PCP connectivity mainly include occipital regions, such as the Occipital Fusiform Gyrus and the left Occipital Pole ([Fig. 4](#f0020){ref-type="fig"}A).Fig. 4Beta-amyloid Load Interacts with Gray Matter GABA and Glutamate on Static Functional Connectivity Networks.Fig. 4

The glutamate and beta-amyloid interaction displayed a different array of altered PCP functional connectivity networks (9 clusters). Positive PCP connectivity were in clusters covering regions of the Cerebellum, the Middle Frontal Gyrus, the right Superior Frontal Gyrus, and the Inferior Frontal Gyrus pars opercularis and similar to GABA, negatively connected clusters covered occipital areas, including the left and right Occipital Fusiform Gyrus, the left and right Lingual Gyrus, the Lateral Occipital Cortex, and the right Temporal Occipital Fusiform Cortex ([Fig. 4](#f0020){ref-type="fig"}B).

Rendered 3D brains and coronal brain slices showing regions with increased (red) connectivity and decreased (blue) PCP connectivity associated with (A) GABA interacting with global beta-amyloid, (B) Glutamate interacting with beta-amyloid. Cluster thresholds for visualization of these clusters were different from the analysis with a voxel height threshold of *p* *\<* 0*.02* (uncorrected) and a cluster threshold of *p* *\<* 0*.05* (FDR-corrected). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

3.4. Dynamic connectivity: Effect of GABA and glutamate and global Beta-amyloid on functional connectivity {#s0070}
----------------------------------------------------------------------------------------------------------

No significant correlations were found between the percentage of positive weights and GABA or with glutamate ([Table 2](#t0010){ref-type="table"}). Moreover, global beta-amyloid did not have any significant correlations with eigenconnectivity weights ([Table 3](#t0015){ref-type="table"}).Table 2Correlations between the percentage of positive weights of each eigenconnectivity and GABA and Glutamate measures in the PCP gray matter.Table 2Eigenconnectivityr-valuep-FDREigenconnectivityr-valuep-FDRGABA10.090.74Glutamate10.210.942−0.420.4120.170.963−0.240.530.030.954−0.170.734−0.080.9250.150.6850.040.846−0.410.256−0.020.970.340.367−0.141.0880.270.458−0.221.0590.130.679−0.190.9210−0.0020.99100.121.08Table 3Correlations between the percentage of positive weights of each eigenconnectivity and cortical global beta-amyloid load.Table 3Eigenconnectivityr-valuep-FDRGlobal ß-amyloid1−0.360.272−0.420.233−0.250.44−0.360.185−0.120.9160.040.9370.30.288−0.110.8190.0020.99100.070.89

3.5. GABA and regional Beta-amyloid relate to dynamic functional connectivity {#s0075}
-----------------------------------------------------------------------------

To explore interactive effects of GABA and glutamate on beta-amyloid networks on a multivariate level, CCA was used. By applying CCA, we explored possible relationships indicated by canonical functions, representing linear combinations of maximal correlation between compared variable sets.

No significant interactive effects on the percentage of positive weights with local beta-amyloid deposition and glutamate were observable. However, CCA indicated a significant difference in the amount of time the eigenconnectivities spent in a positive configuration in subjects with regional beta-amyloid in the Amygdala (*F*(2,21) = 3.51, *p-FDR* *=* *0.048*), Frontal lobe (*F*(2,21) = 3.57, *p-FDR* *=* *0.046*), Hippocampus (*F*(2,21) = 3.66, *p-FDR* *=* *0.04*), Insula (*F*(2,21) = 3.53, *p* *=* 0*.048*) and Striatum (*F*(2,21) = 3.74, *p-FDR* *=* *0.04*) interacting with PCP GABA.

Furthermore, factor cross-loadings derived from CCA indicated that the first network (eigenconnectivity), which captures global-signal fluctuations, is most strongly altered according to regional beta-amyloid and PCP GABA load (*r* *=* −0.496) ([Fig. 5](#f0025){ref-type="fig"}A). The negative sign suggested apreference for globally decreased connectivity over time, related to GABA and beta-amyloid levels. Moreover, strong effect sizes were found for a fronto-occipital network (*r* = 0.27) ([Fig. 5](#f0025){ref-type="fig"}B) and a temporo-parietal network (*r* = 0.27) ([Fig. 4](#f0020){ref-type="fig"}C), which both showed preferences for the positive configuration over time, indicating positive connectivity between involved nodes.Fig. 5Beta-amyloid Load Interacts with Gray Matter GABA, but not Glutamate, on Dynamic Functional Connectivity Networks.Fig. 5

From A-C: Row A illustrates a global network, row B a fronto-occipital network and row C a temporo-parietal network. From left to right: Far left is the eigenconnectivity plots wherein the x- and y-axes represent a regions corresponding to the AAL atlas. Red indicates 'positive' connections and blue indicates 'negative' connections. Alongside, glass brains show the axial, sagittal and coronal views of the 2% strongest connections in each network. Brain regions are illustrated as spherical nodes where the size denotes their degree and their color symbolizes the algebraic sign of the relative node strength (red/yellow for positive, blue/green for negative). The same color scheme is applied for the connections. The scatter plots on the far right depict the relationship between the percentage of positive weights (y-axis) and the first canonical of GABA\*beta-amyloid (x-axis) with corresponding *r*-values to show the strength of this relationship. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

4. Discussion {#s0080}
=============

In this cognitively unimpaired old-aged sample, beta-amyloid was associated with altered PCP connectivity in several clusters, including the frontal, inferior temporal and occipital regions. These beta-amyloid-related connectivity changes were moderated by both GABA and glutamate. Though the interaction between beta-amyloid and glutamate affected PCP connectivity in a different cluster array, obtained data indicate that connectivity changes associated with the interaction between beta-amyloid and GABA may be more prominent in both static and dynamic connectivity networks. Interactive static connectivity changes observed with GABA and beta-amyloid, and also glutamate and beta-amyloid, showed increases in PCP connectivity primarily in frontomedial regions and decreased PCP connectivity in clusters located mainly in occipital regions. However, changes to dynamic connectivity were only found for the interaction of GABA with regional beta-amyloid deposits in the Amygdala, Frontal Lobe, Hippocampus, Insula and Striatum, which affected the percentage of positive weights of a global, a fronto-occipital, and a temporo-parietal network. While GABA and regional beta-amyloid interactions showed decreased global connectivity, fronto-occipital and temporo-parietal connections indicated a preference for increased connectivity.

By applying a previously established approach for performing MRSI in clinical study populations ([@bb0340]), PCP glutamate and GABA were assessed specifically for gray and white matter. This approach included post-processing, i.e. ROI-definition and tissue-segmentation, with state-of-the-art acquisition methods that reduce limitations and exploit benefits of the ultra high magnetic field strength achieved at 7 T, including increased signal to noise ratio and high spatial resolution ([@bb0035]; [@bb0110]; [@bb0185]; [@bb0220]). BOLD fMRI resting state data was investigated using both static and dynamic approaches to provide refined information on intrinsic brain network activity. To this effect established approaches were used for investigating synchronicity of BOLD signal in spatially distinct brain regions for static connectivity ([@bb0130]), and also a sliding window approach for assessing temporal dynamics of brain networks ([@bb0070]; [@bb0285]; [@bb0295]; [@bb0315]).

Our data indicate higher PCP levels of GABA and glutamate in gray compared to white matter. These findings are in agreement with earlier reports for other cortical regions and physiological distribution of neurotransmitters ([@bb0145]; [@bb0205]). Our finding of GABA and glutamate-related functional connectivity accords with earlier 3 T single-voxel MR spectroscopy studies ([@bb0135]; [@bb0250]; [@bb0260]; [@bb0275]). Moreover, preclinical studies using two-photon Ca2+ imaging in mice showed that despite a net reduction in cortical neuronal activity, many neurons near beta-amyloid plaques were *'hyperactive'* ([@bb0055]). Interestingly, the amyloid precursor protein and its cleavage product beta-amyloid 1--42 have been demonstrated to interfere with GABAergic transmission ([@bb0310]; [@bb0405]). The Clinical evidence on excitatory and inhibitory neurotransmission in AD is less accurate, as measuring GABA and glutamate with neuroimaging is technically challenging. Brain glutamate and GABA levels have been demonstrated to be changed in AD ([@bb0020]; [@bb0325]) and furthermore linked to altered brain activity in non-demented adults ([@bb0135]; [@bb0250]; [@bb0260]).

Also, consistent with earlier reports, we find changes in connectivity associated with beta-amyloid deposits prior to signs of cognitive decline or other AD-related symptoms ([@bb0355]; [@bb0365]). Furthermore, a prominent observation in previous literature is increased connectivity with frontal brain regions, which is thought to indicate compensatory changes ([@bb0005]; [@bb0150]; [@bb0380]; [@bb0420]; [@bb3555]; [@bb4555]). This coincides with our finding of GABA and glutamate interacting with global beta-amyloid and PCP connectivity in frontal regions of the brain. We only found dynamic functional connectivity changes for the interaction between GABA and beta-amyloid load. These were specifically localized to regions intimately linked to the DMN and affected in early stages of AD ([@bb0365]). Our finding of globally decreased connectivity and at the same time selectively increased connectivity between fronto-occipital and temporo-parietal nodes may appear counterintuitive at first glance. However, local *'high efficiency'* (hyperconnectivity) in brain regions with long anatomical connections might represent a dynamic strategy to minimise metabolic costs ([@bb0430]).

Prior studies have highlighted a relationship between neuronal excitation and beta-amyloid ([@bb0085]; [@bb0080]; [@bb0210]; [@bb0270]; [@bb0280]). Thus, we expected to see major impacts of glutamate on functional connectivity, when interacting with beta-amyloid, considering its role as a major excitatory neurotransmitter and its implication in long-term potentiation (LTP). However, while our findings suggest stronger effects for the interaction between GABA and beta-amyloid, follow-up studies are needed to confirm our findings. Moreover, by better characterizing the natural history of GABA and beta-amyloid interactions during the course of AD, promise of the GABAergic system as a target for pharmacological intervention may be validated ([@bb0060]).

Although this study provides novel findings and has strengths such as the unique combination of advanced neuroimaging methods, there are limitations that need to be taken into consideration. Due to the long acquisition time of ca. 29 min for completing the FIDLOVS MRSI for one brain region located in the PCP, only a relatively small sized population of cognitively healthy old aged adults could be investigated. For increased power, subsequent studies might use lower spatial MRSI resolution, allowing for a shorter MRSI sequence and larger populations that include cognitively impaired participants. Also, when using lower resolution MRSI sequences, follow-up studies might investigate additional brain regions with high susceptibility to AD pathology, such as the medio-temporal and parietal cortex. Alternatively, the development of novel, innovative PET tracers might provide the means for investigating regional variation of neurotransmitters in AD ([@bb0240]; [@bb0415]). Moreover, while the ultra-high magnetic field strength applied in the current study enabled tissue specific estimation of GABA (and glutamate), due to the lack of spectral editing in our MRSI approach, some overlap between spectral peaks of GABA with other metabolites and macromolecules is to be expected. This imprecision for estimation of GABA is a limitation of our study, which is why careful interpretation and replication of our findings are warranted. Another limitation is the cross-sectional nature of this study. To fully investigate whether the effects of GABA and glutamate in conjunction with beta-amyloid deposits on functional connectivity are more likely pathological in nature or compensatory, it would be ideal to follow-up with a longitudinal study including individuals that vary in progression of AD pathology.

In conclusion, this study confirms earlier non-human studies by providing first evidence of a moderating relationship between GABA and to a lesser degree also glutamate on beta-amyloid related functional brain networks in cognitively unimpaired old-aged humans. Moreover, to our knowledge, this study is the first attempt to implement non-invasive neuroimaging techniques to assess relationships between GABA, glutamate and beta-amyloid on functional connectivity. Additional longitudinal studies are needed to determine how progression of AD may relate to GABA and glutamate levels, and thus exploit novel possibilities for neurotransmitter targeted therapeutic intervention.
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